Endothelial function and its assessment

Bibliography

• MONCADA S, HIGGS A: The L-arginine--pathway. N Engl. I Med. (1993) 329:2002–2020.
   PubMed Web of Science ®Google Scholar
• COHEN R: The role of nitric oxide and other endothelium derived vasoactive substances in vascular disease.. Cardiovasc. Dis. (1995) 38:105–128.
   Google Scholar
• LUESCHER TF, NOLL G: Endothelial dysfunction in the coronary circulation. Cardiovasc. Phannacol. (1994) 24\(Suppl. 3):S16–S26.
   Google Scholar
• YANAGISAWA M, KURIHARA H, KIMURA S et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1988) 332:411–415.
   PubMed Web of Science ®Google Scholar
• DREXLER H: Endothelial dysfunction: clinical implications. Frog. Cardiovasc. Dis. (1997) 39(4):287–324.
   PubMed Web of Science ®Google Scholar
• CLARKSON P, CELERMAJER DS, DONALD AE et al.: Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low-density lipoprotein cholesterol levels.. Coll. Cardiol. (1996) 28(3):573–579.
   Google Scholar
• LUDMER PL, SELWYN AP, SHOOK TL et al.: Paradoxical vasoconstriction induced acetylcholine in atherosclerotic arteries. N. Engl. J. Med. (1986) 315:1046–1051.
   PubMed Web of Science ®Google Scholar
• ENDERLE MD, BENDA N, RM, HAERING HU, PFOHL M: Preserved endothelial function in IDDM patients, but not in NIDDM patients, compared with healthy subjects. Diabetes Care (1998) 21(2):271–277.
   PubMed Web of Science ®Google Scholar
• ENDERLE MD, PFOHL M, KELLERMANN N, HAERING HU, HOFFMEISTER HM: Endothelial function, variables of fibrinolysis and coagulation in smokers and healthy controls. Haemostasis (2000) 30(3):149–158.
   PubMedGoogle Scholar
• PANZA JA, QUYYUMI AA, BRUSH JE Jr, EPSTEIN SE: Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl. I Med. (1990) 323(1):22–27.
   PubMed Web of Science ®Google Scholar
• PALMER RMJ, ASHTON DS, MONCADA S: Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (1988) 333:664–666.
   PubMed Web of Science ®Google Scholar
• BREDT DS, HWANG PM, GLATT CE, LOWENSTEIN C, REED RR, SH: Cloned and expressed nitric oxide synthase structurally resembles cytochrome P450 reductase. Nature (1991) 351:714.
   PubMed Web of Science ®Google Scholar
• FURCHGOTT RE ZAWADZKI JV: The obligatory role of endothelial cells in the of arterial smooth muscle by acetylcholine. Nature (1980) 299:373–376.
   Google Scholar
• VALLANCE P, COLLIER V, S: Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet (1989) 2:997–1000.
   PubMed Web of Science ®Google Scholar
• QUYYUMI AA, DAKAK N, ANDREWS NP, GILLIGAN DM, PANZA JA, CANNON ROR: Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation (1995) 92:320–326.
   PubMed Web of Science ®Google Scholar
• POHL U, HOLTZ J, BUSSE R, E: Crucial role of endothelium in the vasodilator response to increased flow vivo. Hypertension (1986) 8:37–44.
   PubMed Web of Science ®Google Scholar
• LUESCHER TF, VANHOUTTE PM: The endothelium: modulator of cardiovascular function. CRC Press, Florida, USA (1990).
   Google Scholar
• LUESCHER TF, BOULANGER CM, YANG Z, NOLL G, DOHI Y: Interactions between endothelium-derived relaxing and contracting factors in health and cardiovascular disease. Circulation (1993) 87:36–44.
   Web of Science ®Google Scholar
• KUBES P, SUZUKI M, GRANGER DN: Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Nati Acad. Li. USA (1991) 81:4651–4655.
   Google Scholar
• DAVIES MJ, GORDON JL, AJ et al.: The expression of the molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J. Pathol (1993) 171:223–229.
   PubMed Web of Science ®Google Scholar
• SAKAI A, KUME N, NISHI E, TANOUE K, MIYASAKA M, KITA T: P-selectin and vascular cell adhesion molecule-1 are focally expressed in aortas of hypercholesterolemic rabbits before intimal accumulation of macrophages and T lymphocytes. Arterioscler. Thromb. Vase. Biol. (1997) 17:310–316.
   PubMed Web of Science ®Google Scholar
• ROSS R: Atherosclerosis: an inflammatory disease. N Engl. J. Med. (1999) 340:115–126.
   PubMed Web of Science ®Google Scholar
• •Review on the inflammatory hypothesis of atherosclerosis.
   Google Scholar
• LIBBY P: Coronary artery injury and thebiology of atherosclerosis: inflammation, thrombosis, and stabilization.. J. Cardiol (2000) 86:3J–8J.
   Google Scholar
• RIDKER PM, HENNEKENS CH, ROITMAN-JOHNSON B, MJ, ALLEN J: Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet (1998) 351(9096):88–92.
   PubMed Web of Science ®Google Scholar
• RADOMSKI MW PALMER RM, MONCADA S: Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet (1987) 2(8567):1057–1058.
   PubMed Web of Science ®Google Scholar
• •Important early paper on NO in the vasculature.
   Google Scholar
• MICHELSON AD, BENOIT SE, FURMAN MI et al.: Effects of nitric oxide/ EDRF on platelet surface glycoproteins. Am. J. Physiol (1996) 270(5 Part 2):H1640–H1648.
   Google Scholar
• KADER KN, AKELLA R, ZIATS NP et al: eN0S-overexpressing endothelial cells inhibit platelet aggregation and smooth muscle proliferation in vitro. Tissue Eng. (2000) 6:241–251.
   PubMedGoogle Scholar
• PEARSON JD: Endothelial cell function and thrombosis. Baillieres Best Pract. Res. Clin. Haematol (1999) 12:329–341.
   PubMed Web of Science ®Google Scholar
• PEARSON JD: Normal endothelial cell function. Lupus (2000) 9:183–188.
   PubMed Web of Science ®Google Scholar
• SEIGNEUR M, DUFOURCO P, CONRI C et al.: Plasma thrombomodulin: new approach of endothelium damage. Int. Angiol. (1993) 12:355–359.
   PubMed Web of Science ®Google Scholar
• RUBANYI GM: The role of endothelium in cardiovascular homeostasis and disease.. Pharmacol (1993) 22\(Suppl. 4):S1–514.
   Google Scholar
• DZAU VJ, GIBBONS GH: Endothelium and growth factors in vascular remodeling in hypertension. Hypertension (1991) 18(Suppl. III):III-115-III–121.
   Google Scholar
• BOBIK A, CAMPBELL JH: Vascular derived growth factors: cell biology, pathophysiology and pharmacology. Pharmacol Rev. (1993) 45:1–42.
   PubMed Web of Science ®Google Scholar
• CASTELLOT JJ, ADD ONIZIO ML, ROSENBERG RD, KARNOWSKY MJ: Cultured endothelial cells produce a heparin-like inhibitor of smooth muscle growth. J. Cell Biol. (1981) 90:372–379.
   PubMed Web of Science ®Google Scholar
• BOBIK A, GROOMS A, MILLAR JA, MITCHELL A, GRINPUNKEL S: Growth factor activity of endothelin on vascular smooth muscle. Am. J. Physiol (1990) 258:C408–C415.
   PubMed Web of Science ®Google Scholar
• JANAKIDEVI K, FISHER MA, VECCHIO PJ, TIRUPPATHI C, FIGGE J, MALIK AB: Endothelin- 1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle cells. Am. J. Physiol (1992) 263:C1295–C1301.
   PubMed Web of Science ®Google Scholar
• SHIROTANI M, YUI Y, HATTORI R, KAWAI C: U-61, 431F, a stable prostacyclin analogue, inhibits the proliferation of bovine vascular smooth muscle cells with little antiproliferative effect on endothelial cells. Prostaglandins (1991) 41:97–110.
   PubMedGoogle Scholar
• ROSS R: The pathogenesis of: a perspective for the 1990s. Nature (1993) 362:801–809.
   PubMed Web of Science ®Google Scholar
• RUBANYI GM, POLOKOFF MA: Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. (1994) 46:325–415.
   PubMed Web of Science ®Google Scholar
• VITA JA, TREASURE CB, NABEL EG et al.: Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation (1990) 81:491–497.
   PubMed Web of Science ®Google Scholar
• SCHACHINGER V, BRITTEN MB, ZEIHER AM: Prognostic impact of coronary vasodilator function on adverse long-term outcome of coronary heart disease. Circulation (2000) 101:1899–1906.
   PubMed Web of Science ®Google Scholar
• HEITZER T, SCHLINZIG T, KROHN K,MEINERTZ T, MUNZEL T: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation (2001) 104(22):2673–2678.
   PubMed Web of Science ®Google Scholar
• LIP GYH, BLANN A: von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc. Res. (1997) 34:255–365.
   Google Scholar
• •Comprehensive review on vWF as an endothelial marker.
   Google Scholar
• BLANN A: von Willebrand factor and the endothelium in vascular disease. BE J. Biomed. Li. (1993) 50:125–134.
   PubMed Web of Science ®Google Scholar
• BLANN AD, TABERNER DA: A reliable marker of endothelial cell dysfunction: does it exist? BE J. Haematol (1995) 90:244–248.
   Google Scholar
• BOWIE EJW, SOLBERG LA, FASS DN et al.: Transplantation of normal bone marrow into a pig with severe von Willebrand disease../. Clin. Invest. (1986) 78:26–30.
   Google Scholar
• VAN MOURIK JA, BOERTJES R, HUISVELD IA et al: von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial perturbation. Blood (1999) 94:179–185.
   PubMed Web of Science ®Google Scholar
• HIROKAWA K, AOKI N: Up-regulation of thrombomodulin in human umbilical vein endothelial cells in vitro. J. Biochem. (1990) 108:839–845.
   PubMed Web of Science ®Google Scholar
• POTTINGER BE, READ RC, PALEOLOG EG, HIGGINS PG, PEARSON JD: von Willebrand factor is an acute phase reactant in man. Thromb. Res. (1989) 53:387–394. 73:1586-91.
   Google Scholar
• HAINES AP, HOWARTH D, WR et al.: Haemostatic variables and the outcome of myocardial infarction.. Haemost. (1983) 50:800–803.
   Google Scholar
• JANSSON J, NILSSON TK, 0: von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br. Heart J. (1991) 66:351–355.
   PubMedGoogle Scholar
• MEADE TW, COOPER JA, STIRLING Y,HOWARTH DJ, RUDDOCK V, MILLER GJ: Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br. J. Haematol. (1994) 88:601–607.
   PubMed Web of Science ®Google Scholar
• BICKEL C, RUPPRECHT HJ, BLANKENBERG S et al.: Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am. J. Cardiol (2002) 89:901–908.
   PubMed Web of Science ®Google Scholar
• OGAWA T, KIMOTO M, SASAOKA K: Occurrence of a new enzyme catalyzing the conversion of AG,AG-dimethyl-L-arginine to L-citrulline in rats. Biochem. Biophys. Res. Commun. (1987) 148:671–677.
   PubMed Web of Science ®Google Scholar
• KAKIMOTO Y, AKAZAWA S: Isolation and identification of AG, AG-, and NG-dimethyl-arginine, Nmono-, di-, and trimethyllysine, and glucosylgalactosyl-, and galactosy1-8-hydroxylysine from human urine. J. Biol Chem. (1970) 245:5751–5758.
   PubMed Web of Science ®Google Scholar
• VALLANCE P, LEONE A, CALVER A, COLLIER J, MONCADA S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet (1992) 339:572–575.
   PubMed Web of Science ®Google Scholar
• MATSUOKA H, ITOH S, KIMOTO M et al: Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension (1997) 29:242–247.
   PubMed Web of Science ®Google Scholar
• BOEGER RH, BODE-BOGER SM, SZUBA A et al: Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation (1998) 98:1842–1847.
   PubMed Web of Science ®Google Scholar
• MIYAZAKI H, MATSUOKA H, COOKE JP et al: Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation (1999) 99:1141–1146.
   PubMed Web of Science ®Google Scholar
• ABBASI F, ASAGMI T, COOKE JP et al: Plasma concentrations of asymmetric dimethylarginine are increased in patients with Type 2 diabetes mellitus.. J. Cardiol. (2001) 88:1201–1203.
   Web of Science ®Google Scholar
• STUHLINGER MC, ABBASI F, CHU JW et al.: Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA (2002) 287:1420–1426.
   PubMed Web of Science ®Google Scholar
• COOKE JP: Does ADMA cause endothelial dysfunction?. Thromb. Vasc. Biol. (2000) 20:2032–2037.
   PubMed Web of Science ®Google Scholar
• ITO A, TSAO PS, ADIMOOLAM S, KIMOTO M, OGAWA T, COOKE JP: Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation (1999) 99:3092–3095.
   PubMed Web of Science ®Google Scholar
• COOKE JP, ANDON NA, GIRERD XJ,HIRSCH AT, CREAGER MA: Arginine restores cholinergic relaxation of hypercholesterolemic rabbit thoracic aorta. Circulation (1991) 83:1057–1062.
   PubMed Web of Science ®Google Scholar
• COOKE JP, DZAU VJ: Derangements of the nitric oxide synthase pathway, L-arginine, and cardiovascular diseases. Circulation (1997) 96:379–382.
   PubMed Web of Science ®Google Scholar
• CREAGER MA, GALLAGHER SJ, GIRERD XJ, COLEMAN SM, DZAU VJ, COOKE JP: L-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans.. Invest. (1992) 90:1248–1253.
   Google Scholar
• DREXLER H, FISCHELL TA, PINTO FJ et al.: Effect of L-arginine on coronary endothelial function in cardiac transplant recipients: relation to vessel wall morphology. Circulation (1994) 89:1615–1623.
   PubMed Web of Science ®Google Scholar
• MASAKI T, VANE JR, PM: International Union of Pharmacology nomenclature for endothelin receptors. Pharmacol. Rev. (1994) 46:137–142.
   PubMed Web of Science ®Google Scholar
• SPIEKER LE, NOLL G, FT, LUSCHER TF: Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?' Am. Coll Cardiol. (2001) 37:1493–1505.
   PubMed Web of Science ®Google Scholar
• ARM H, HORI S, ARAMORI I, OHKUBO H, NAKANISHI S: Cloning and expression of a cDNA encoding an endothelin receptor. Nature (1990) 348:730–732.
   PubMed Web of Science ®Google Scholar
• SCHINI VB, VANHOUTTE PM: Endothelin-1: a potent vasoactive peptide. Pharmacol. Toxicol. (1991) 69:1–7.
   Google Scholar
• SEO B, OEMAR BS, SIEBERMANN R, VON SEGESSER L, LUESCHER TF: Both ETA and ETB recetors mediate contraction to endothelin-1 in human blood vessels. Circulation (1994) 89:1203–1208.
   PubMed Web of Science ®Google Scholar
• VERHAAR MC, STRACHAN FE, NEWBY DE et al: Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation (1998) 97:752–756.
   PubMed Web of Science ®Google Scholar
• YOSHIZUMI M, KURIHARA H, MORITA T et al: Interleukin 1 increases the production of endothelin-1 by cultured endothelial cells. Biochem. Biophys. Res. Commun. (1990) 166:324–329.
   PubMed Web of Science ®Google Scholar
• YOSHIZUMI M, KURIHARA H, SUGIYAMA T et al.: Hemodynamic shear stress stimulates endothelin production by cultured endothelial cells. Biochem. Biophys. Res. Commun. (1989) 161:859–864.
   PubMed Web of Science ®Google Scholar
• KOUREMBANAS S, MARSDEN PA, McQUILLAN LP, FALLER DV: Hypoxia induces endothelin gene expression and secretion in cultured human endothelium.. Invest. (1991) 88:1054–1057.
   Google Scholar
• HAYNES WG, WEBB DJ: Endothelin as aregulator of cardiovascular function in health and disease. J. Hypertens. (1998) 16:1081–1098.
   PubMed Web of Science ®Google Scholar
• MORISE T, TAKEUCHI Y, KAWANO M,KONI I, TAKEDA R: Increased plasma levels of immunoreactive endothelin and von Willebrand factor in NIDDM patients. Diabetes Care (1995) 18:87–89.
   PubMed Web of Science ®Google Scholar
• COLUCCI WS: Myocardial endothelin: does it play a role in myocardial failure? Circulation (1996) 93:1069–1072.
   PubMed Web of Science ®Google Scholar
• SELIGMAN BG, BIOLO A, POLANCZYK CA, GROSS JL, CLAUSELL N: Increased plasma levels of endothelin 1 and von Willebrand factor in patients with Type 2 diabetes and dyslipidaemia. Diabetes Care (2000) 23:1395–1400.
   PubMed Web of Science ®Google Scholar
• FLAVAHAN N, VANHOUTTE PM: Endothelial cell signalling and endothelial dysfunction. Am. J. Hypertens. (1995) 8\(Suppl. 5):285–415.
   Google Scholar
• BOULANGER CM, TANNER FC, BEA ML, HAHN AWA, WERNER A, LUESCHER TF: Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ. Res. (1992) 70:1191–1197.
   PubMed Web of Science ®Google Scholar
• BOHM F, AHLBORG G, PERNOW J: Endothelin-1 inhibits endothelium-dependent vasodilatation in the human forearm: reversal by ETA receptor blockade in patients with atherosclerosis. Clin. Sci. (2002) 102(3):321–327.
   PubMed Web of Science ®Google Scholar
• DAVIES MG, HAGEN P-0: The vascular endothelium: a new horizon. Ann. Surg. (1993) 218:593–609.
   PubMed Web of Science ®Google Scholar
• CYBULSKY MI, GIMBRONE MA Jr: Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science (1991) 251:788–791.
   PubMed Web of Science ®Google Scholar
• LI H, CYBULSKY MI, MA Jr, LIBBY P: An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler. Thromb. (1993) 13:197–204.
   PubMed Web of Science ®Google Scholar
• O'BRIEN KD, ALLEN MD, McDONALD TO et al: Vascular cell molecule-1 is expressed in human coronary atherosclerotic plaques: implications for the mode of progression of advanced coronary atherosclerosis. Circulation (1993) 92:945–951.
   Google Scholar
• DE CATERINA R, BASTA G, G et al: Soluble vascular cell molecule-1 as a biohumoral correlate of atherosclerosis.. Thromb. Vasc. Biol. (1997) 17:2646–2654.
   PubMed Web of Science ®Google Scholar
• MALMQVIST K, WALLEN HN, HELD C, KAHAN T: Soluble cell adhesion molecules in hypertensive concentric left ventricular hypertrophy. I Hypertens. (2002) 20(8):1563–1569.
   PubMed Web of Science ®Google Scholar
• GASIC S, WAGNER OF, FASCHING P et al: Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive Type II diabetic patients with microalbuminuria.. J. Hypertens. (1999) 12(2 Part 1):217–222.
   Google Scholar
• GEARING AJ, NEWMAN W: Circulating adhesion molecules in disease.. Today(1993) 14:506–512.
   Google Scholar
• PIGOTT R, DILLON LP, HEMINGWAY IH, GEARING AJ: Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants and cytokine activated cultured endothelial cells. Biochem. Biophys. Res. Commun. (1992) 187:584–589.
   PubMed Web of Science ®Google Scholar
• BLANN AD, LIP GYH: The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications. Blood Coagul. Fibrinolysis (1998) 9:297–306.
   PubMed Web of Science ®Google Scholar
• BLANN AD, TSE W, MAXWELL SJ, WAITE MA: Increased levels of the soluble adhesion molecule E-selectin in essential hypertension. Hypertens. (1994) 12:925–928.
   Web of Science ®Google Scholar
• BLANN AD, WAITE MA: von Willebrandfactor and soluble E-selectin in hypertension: influence of treatment and value in predicting the progression of atherosclerosis. Coron. Artery Dis. (1996) 7:143–147.
   PubMed Web of Science ®Google Scholar
• ALEXIOU D, KARAYIANNAKIS AJ, SYRIGOS KN et al: Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery. Eur. J. Cancer (2001) 37:2392–2397.
   PubMed Web of Science ®Google Scholar
• BLANKENBERG S, RUPPRECHT HJ, BICKEL C et al: Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation (2001) 104:1336–1342.
   PubMed Web of Science ®Google Scholar
• BRAMAN RS, HENDRIX SA: Nanogram nitrite and nitrate determination in environmental and biological materials by vanadium (III) reduction with chemiluminescence detection. Anal. Chem. (1989) 61(24):2715–2718.
   PubMed Web of Science ®Google Scholar
• TSIKAS D, BOGER RH,-BOGER SM, GUTZKI FM, FROLICH JC: Quantification of nitrite and nitrate in human urine and plasma as pentafluorobenzyl derivatives by gas chromatography-mass spectrometry using their 15N-labelled analogs. J. Chromatogr. B. Biomed. Appl. (1994) 661 (2) :185–191.
   PubMedGoogle Scholar
• BOLOTINA VM, NAJIBI S, JJ, PAGANO PJ, RA: Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature (1994) 368(6474):850–853.
   PubMed Web of Science ®Google Scholar
• BOGER RH, BODE-BOGER SM, GERECKE U, GUTZKI FM, TSIKAS D, FROLICH JC: Urinary NO3-excretion as an indicator of nitric oxide formation in vivo during oral administration of L-arginine or L-NAME in rats. Clin. Exp. Pharmacol. Physiol. (1996) 23:11–15.
   PubMed Web of Science ®Google Scholar
• VIINIKKA L: Nitric oxide as a challenge for the clinical chemistry laboratory. Scandj Clin. Lab. Invest. (1996) 56(7):577–581.
   PubMed Web of Science ®Google Scholar
• FICHTLSCHERER S, ZEIHER AM: Endothelial dysfunction in acute coronary syndromes: association with elevated C-reactive protein levels. Ann. Med. (2000) 32(8):515–518.
   PubMed Web of Science ®Google Scholar
• RIDKER PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation (2003) 107:363–369.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, RIFAI N, ROSE L, BURING JE, COOK NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Eng]. J. Med. (2002) 347:1557–1565.
   PubMed Web of Science ®Google Scholar
• •Important paper on CRP as a prognostic marker for cardiovascular events.
   Google Scholar
• VERMA S, WANG CH, LI SH et al: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation (2002) 106(8):913–919.
   PubMed Web of Science ®Google Scholar
• SPEIDL WS, ZEINER A, M et al.: An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion. J. Am. Coll Cardiol. (2005) 45(1):30–34.
   PubMed Web of Science ®Google Scholar
• HRISTOV M, WEBER C: Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance J. Cell. Mol. Med. (2004) 8(4):498–508.
   PubMed Web of Science ®Google Scholar
• DIMMELER S, AICHER A, VASA M, MILDNER-RIHM C, ADLER K: HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the P13-kinase/Akt pathway, J. Clin. Invest. (2001) 108:391–397,
   PubMed Web of Science ®Google Scholar
• FADINI GP, MIORIN M, FACCO M, BONAMICO S, BAESSO I: Circulating endothelial progenitor cells are reduced in peripheral vascular complications of Type 2 diabetes mellitus. Am. Coll Cardiol. (2005) 45(9):1449–1457.
   PubMed Web of Science ®Google Scholar
• BLANN AD, WOYWODT A, BERTOLINI F et al.: Circulating endothelial cells. Biomarker of vascular disease. Thromb. Haemost. (2005) 93(2):228–235.
   PubMed Web of Science ®Google Scholar
• FREESTONE B, LIP GYH, CHONG AY, NADAR S, LEE KW, BLANN AD: Circulating endothelial cells in atrial fibrillation with and without acute cardiovascular disease. Thromb. Haemost. (2005) 94:702–706.
   PubMed Web of Science ®Google Scholar
• LEE KW, LIP GY, TAYEBJEE M, FOSTER W, BLANN AD: Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood (2005) 105(2):526–532.
   PubMed Web of Science ®Google Scholar
• HALCOX JP, SCHENKE WH, ZALOS G et al.: Prognostic value of coronary vascular endothelial dysfunction. Circulation (2002) 106(6):653–658.
   PubMed Web of Science ®Google Scholar
• HASDAI D, LERMAN A: The assessment of endothelial function in the cardiac catheterisation laboratory in patients with risk factors for atherosclerotic coronary artery disease. Herz (1999) 24:544–547.
   PubMed Web of Science ®Google Scholar
• DREXLER H, ZEIHER AM: Endothelial function in human coronary arteries in vivo. Focus on hypercholesterolemia. Hypertension (1991) 18\(Suppl. 4):I190–1199.
   Google Scholar
• DUFFY SJ, CASTLE SF, HARPER RW, MEREDITH IT: Contribution of prostanoids and nitric oxide to resting flow, metabolic vasodilation, and flow-mediated dilation in human coronary circulation. Circulation (1999) 100(19):1951–1957
   PubMed Web of Science ®Google Scholar
• RIZZONI D, PORTERI E, CASTELLANO M et al: Vascular hypertrophy and remodeling in secondary hypertension. Hypertension (1996) 28:785–790.
   PubMed Web of Science ®Google Scholar
• MULVANY MJ, HANSEN PK, AALKJAER C: Direct evidence that the greater contractility of resistance vessels in spontaneously hypertensive rats is associated with a narrowed lumen, a thickened media, and an increased number of smooth muscle cell layers. Circ. Res. (1978) 43:854–864.
   PubMed Web of Science ®Google Scholar
• HEAGERTY AM, AALKJAER C, BUND SJ, KORSGAARD N, MJ: Small artery structure in hypertension: dual process of remodeling and growth. Hypertension (1993) 21:391–397.
   PubMed Web of Science ®Google Scholar
• REDDY KG, NAIR NR, SHEEHAN HM, HODGSON JM: Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for coronary artery disease. Circulation (1994) 23:833–843.
   Google Scholar
• GORDON JB, GANZ P, NABEL EG, FISH ZEBEDE J, MUD GE GH: Atheroscelerosis influences the vasomotor response of epicardial coronary arteries to exercise. J. Clin. Invest. (1989) 83:1946–1952.
   PubMed Web of Science ®Google Scholar
• SUWAIDI JA, HAMASAKI S, ST, NISHIMURA RA, HOLMES DR Jr, LERMAN A: Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation (2000) 101(9):948–954.
   PubMed Web of Science ®Google Scholar
• ANDERSON TJ, MEREDITH IT, YEUNG AC, FREI B, SELWYN AP, GANZ P: The effect of cholesterol lowering and antioxidant therapy on endothelial dependent coronary vasomotion. N Engl. J. Med. (1995) 332:448–493.
   Google Scholar
• BERDEAUX A, DUBOIS-RANDE JL, HITTINGER L: Nitrates et dysfonctionnement vasculaire coronaire d'endothelium [Nitrates and coronary vascular endothelium dysfunction.] Ann. Cardiol Angeiol. (Paris) (1997) 46(7):391–398.
   Google Scholar
• HOKANSON DE, SUMNER DS, STRANDNESS DE Jr: An electrically calibrated plethysmograph for direct of limb blood flow. IEEE Trans. Biomed Eng. (1975) 22 (1): 25–29.
   PubMedGoogle Scholar
• JOHNSTONE MT, CREAGER SJ, SCALES KM, CUSCO JA, LEE BK, CREAGER MA: Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation (1993) 88 (6) :2510–2516.
   PubMed Web of Science ®Google Scholar
• PANZA JA, QUYYUMI AA, TS, EPSTEIN SE: Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J. Am. Cardiol (1993) 21(5):1145–1151.
   Web of Science ®Google Scholar
• LIND L, SARABI M, MILLGARD J: Methodological aspects of the evaluation of endothelium-dependent vasodilatation in the human forearm. OM Physiol (1998) 18(2):81–87.
   Web of Science ®Google Scholar
• WEBB DJ: The pharmacology of human blood vessels in vivo. J. Vasc. Res. (1995) 32(1):2–15.
   PubMed Web of Science ®Google Scholar
• TADDEI S, VIRDIS A, GHIADONI L, ULERI S, MAGAGNA A, SALVETTI A: Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients. Hypertension (1997) 30(6):1606–1612.
   PubMed Web of Science ®Google Scholar
• JOHNS, SCHLAICH M, LANGENFELD M et al: Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation (1998) 98(3):211–216.
   PubMed Web of Science ®Google Scholar
• GOULD KL, MARTUCCI JP, GOLDBERG DI et al: Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation (1994) 89 (4) :1530–1538.
   Google Scholar
• UREN NG, MELIN JA, DE BRUYNE B, WIJNS W, BAUDHUIN T, CAMICI PG: Relation between myocardial blood flow and the severity of coronary-artery stenosis. N. Engl. J. Med. (1994) 330(25):1782–1728.
   PubMed Web of Science ®Google Scholar
• PITKANEN OP, RAITAKARI OT, NIINIKOSKI H et al.: Coronary flow reserve is impaired in young men with familial hypercholesterolemia. J. Am. Coll Cardiol (1996) 28 (7) :1705–1711.
   PubMed Web of Science ®Google Scholar
• RAITAKARI OT, PITKANEN OP, LEHTIMAKI T et al.: In vivo low density lipoprotein oxidation relates to coronary reactivity in young men. J. Am. Cardiol (1997) 30(1):97–102.
   Web of Science ®Google Scholar
• LAINE H, RAITAKARI OT, H et al: Early impairment of coronary flow reserve in young men with borderline hypertension. J. Am. Cardiol (1998) 32(1):147–153.
   Web of Science ®Google Scholar
• CZERNIN J, BARNARD RJ, SUN KT et al.: Effect of short-term cardiovascular conditioning and low-fat diet on myocardial blood flow and flow reserve. Circulation (1995) 92(2):197–204.
   PubMed Web of Science ®Google Scholar
• HUGGINS GS, PASTERNAK RC, ALPERT NM, FISCHMAN AJ, GEWIRTZ H: Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse. Circulation (1998)98(13):1291–1296.
   PubMed Web of Science ®Google Scholar
• SONKA M, LIANG W, LAUER RIVI: Automated analysis of brachial ultrasound image sequences: early detection of cardiovascular disease via surrogates of endothelial function. IEEE Trans. Med. 1meg:frig (2002) 21(10):1271–1279.
   Google Scholar
• HIJMERING ML, STROES ES, PASTERKAMP G, SIEREVOGEL M, BANGA JD, RABELINK TJ: Variability of flow mediated dilation: consequences for clinical application. Atherosclerosis (2001)157(2):369–373.
   PubMed Web of Science ®Google Scholar
• SORENSEN KE, CELERMAJER DS, SPIEGELHALTER DJ et al: Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibilty. Br. Heart J. (1995) 74:247–253.
   PubMedGoogle Scholar
• CELERMAJER DS: Endothelial; Does it matter? Is it reversible? J. Am. Coll Cardiol (1997) 30:325–333.
   PubMed Web of Science ®Google Scholar
• JOANNIDES R, HAEFELI WE, LINDER L et al: Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation (1995) 91:1314–1319.
   PubMed Web of Science ®Google Scholar
• TAKSE B, UEHATA A, AKIMA T et al: Endothelial-dependent flow-mediated vasodilatation in coronary and brachial arteries in suspected coronary artery disease. Am. J. Cardiol (1998) 82:1535–1539.
   PubMed Web of Science ®Google Scholar
• CELERMAJER DS, SORENSEN KE, GOOCH VM et al: Non-invasive detection of endothelial dysfunction in and adults at risk of atherosclerosis. (1992) 340(8828):1111–1115.
   Google Scholar
• AGEWALL S, DOUGHTY RN, BAGG W et al: Comparison of ultrasound assessment of flow-mediated dilatation in the radial and brachial artery with upper and forearm cuff positions. Chi]. Physiol. (2001) 21:9–14.
   Google Scholar
• LEESON P, THORNE S, DONALD A, MULLEN M, CLARKSON P, DEANFIELD J: Non-invasive of endothelial function: effect of brachial artery dilatation of graded endothelial dependent and independent stimuli. Heart (1997) 78:22–27.
   PubMed Web of Science ®Google Scholar
• UEHATA A, LIEBERMANN EH, GERHARD MD et al: Noninvasive assessment of endothelium- dependent flow-mediated dilation of the brachial artery. Vase. Med. (1997) 997:87–92.
   Google Scholar
• HARDIE KL, KINLAY S, HARDY DB, WLODARCZYK J, SILBERBERG JS, FLETCHER PJ: Reproducibility of brachial ultrasonography and flow-mediated dilation (FMD) for assessing endothelial function. Aust. NZI. Med. (1997) 27:649–652.
   PubMedGoogle Scholar
• VOGEL RA CORRETTI MC, PLOTNICK GD: The effect of a single high-fat meal on endothelial function in healthy subjects. Am. Cardiol. (1997) 79:350–354.
   PubMed Web of Science ®Google Scholar
• HASHIMOTO M, AKISHITA M, ETO M et al.: Modulation of endothelium-dependent dilatation of the brachial artery by sex and menstrual cycle. Circulation (1995) 92:3431–3435.
   PubMed Web of Science ®Google Scholar
• CORRETTI MC, ANDERSON TJ, BENJAMIN EJ et al.: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J. Am. Coll. Cardiol. (2002) 39:257–265.
   PubMed Web of Science ®Google Scholar
• SORENSEN KE, CELERMAJER DS, GEORGAKOPOULUS D, HATCHER G, BETTERIDGE DJ, DEANFIELD JE: Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolaemia and is related to the lipoprotein (a) level. J. Clin. Invest. (1994) 93:50–55.
   PubMed Web of Science ®Google Scholar
• RAITAKARI OT, ADAMS MR, CELERMAJER DS: Effect of Lp(a) on the early functional and structural changes of atherosclerosis. Arterioscler. Thromb. Vase. Biol. (1999) 19(4):990–995.
   PubMed Web of Science ®Google Scholar
• DENG YB, WANG XF, LE GR, ZHANG QP, LI CL, ZHANG YG: Evaluation of endothelial function in hypertensive elderly patients by high-resolution ultrasonography. Clin. Cardiol. (1999) 22:705–710.
   PubMed Web of Science ®Google Scholar
• WATTS GF, O'BRIEN SF, SILVESTER W, MILLAR JA: Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidaemia. Clin. Sci. (Cokh ) (1996) 91:567–573.
   PubMed Web of Science ®Google Scholar
• CELERMAJER DS, SORENSEN KE, SPIEGELHALTER DJ, GEORGAKOPOULOS D, ROBINSON J, DEANFIELD JE: Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J. Am. Coll Cardiol (1994) 24(2):471–476.
   PubMed Web of Science ®Google Scholar
• RAITAKARI OT, ADAMS MR, McCREDIE RJ, GRIFFITHS KA, CELERMAJER DS: Arterial endothelial dysfunction related to passive smoking is potentially reversible in healthy young adults. Ann. Intern. Med. (1999) 130(7):578–581.
   PubMed Web of Science ®Google Scholar
• TAMAI O, MATSUOKA H, ITABE H, WADA Y, KOHNO K, IMAIZUMI T: Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation (1997) 95(1):76–82.
   PubMed Web of Science ®Google Scholar
• STROES ES, KOOMANS HA, BRUIN TW, RABELINK TJ: Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet (1995) 346(8973):467–471.
   PubMed Web of Science ®Google Scholar
• ANDREWS TC, WHITNEY EJ, GREEN G, KALENIAN R, BE: Effect of gemfibroze niacin*/ cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels 160 mg/d1 and high-density lipoprotein cholesterol levels 40 mg/c11. Am. J. Cardiol (1997) 80(7):831–835.
   PubMed Web of Science ®Google Scholar
• SIMONS LA, SULLIVAN D, SIMONS J, CELERMAJER DS: Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia. Atherosclerosis (1998) 137(1):197–203.
   PubMed Web of Science ®Google Scholar
• DUPUIS J, TARDIF JC, CERNACEK P, THEROUX P: Cholesterol reduction improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation (1999) 99(25):3227–3233.
   PubMed Web of Science ®Google Scholar
• O'DRISCOLL G, GREEN D, RR: Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation (1997) 95(5):1126–1131.
   PubMed Web of Science ®Google Scholar
• BRUSH JEJ, CANNON RO, WH et al: Angina due to coronary micraovascular disease in hypertensive patients without left ventricular hypertrophy. N Eng]. I Med. (1988) 319:1302–1307.
   PubMed Web of Science ®Google Scholar
• HASDAI D, GIBBONS RJ, DRJ et al: Coronary endothelial dysfunction is associated with myocardial perfusion defects. Circulation (1997) 96:3390–3395.
   PubMed Web of Science ®Google Scholar
• COHN JN: Arterial compliance to stratify cardiovascular risk: more precision in therapeutic decision making.. J. Hypertens. (2001) 14:258S-263S (Supplement).
   Google Scholar
• MUIESAN ML, SALVETTI M, MONTEDURO C et al.: Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension. Hypertension (1999) 33(1 Part 2):575–580.
   Google Scholar
• WEISS D, KOOLS JJ, TAYLOR WR: Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation (2001) 103(3):448–454.
   PubMed Web of Science ®Google Scholar
• RAJAGOPALAN S, KURZ S, MUENZEL T et al: Angiotensin II mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alteration of vasomotor tone../. Clin. Invest. (1996) 97: 1916-1923.
   Google Scholar
• SORESCU D, GRIENDLING KK: Reactive oxygen species, mitochondria, and NAD (P)H oxidases in the development and progression of heart failure.. Heart Fail. (2002) 8(3):132–140.
   Google Scholar
• GRIENDLING KK, ALEXANDER RW: Oxidative stress and cardiovascular disease. Circulation (1997) 96:3264–3265.
   PubMed Web of Science ®Google Scholar
• LUESCHER TF, VANHOUTTE PM, RAIJ L: Antihypertensive treatment normalizes decreased endothelium-dependent relaxations in rats with salt- hypertension. Hypertension (1987) 9(6 Part 2) :111193–111197.
   Google Scholar
• RODRIGO E, MAESO R,-GARCIA R et al: Endothelial dysfunction in spontaneously hypertensive: consequences of chronic treatment186.with losartan or captopril. Hypertens. (1997) 15(6):613–618.
   Google Scholar
• CREAGER MA, RODDY MA: Effect of captopril and enalapril on endothelial function in hypertensive patients. (1994) 24(4):499–505.187.
   Google Scholar
• RIZZONI D, MUIESAN ML, E et al.: Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy.. (1997) 15(2):197–204.188.
   Google Scholar
• THYBO NK, STEPHENS N, COOPER A, AALKJAER C, HEAGERTY AM, MULVANY MJ: Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. (1995) 25\(Part 1):474–481.189.
   Google Scholar
• SCHIFFRIN EL, DENG LY, P: Effects of a13-blocker or a converting enzyme inhibitor on small arteries in essential hypertension. Hypertension (1994) 23:83–91.
   PubMed Web of Science ®Google Scholar
• SCHIFFRIN EL, DENG LY,190. P: Progressive in the structure of resistance of hypertensive patients after 2 years treatment with an angiotensin I- enzyme inhibitor: comparison effects of a 13-blocker. Am. J. Hypertens.191.(1995) 8:229-236.
   Google Scholar
• RUSCHITZKA F, NOLL G, TF: Angiotensin converting enzyme inhibitors and vascular protection in hypertension. ./. Cardiovasc. Pharmacol (1999) 34\(Suppl. 1):53–512.
   Google Scholar
• HORNIG B, DREXLER H: Endothelial192.function and bradykinin in humans. Drugs (1997) 54\(Suppl. 5):42–47.
   Google Scholar
• HORNIG B, KOHLER C, DREXLER H: Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation (1997) 95:1115-1118.193.
   Google Scholar
• GRIENDLING KK, SORESCU D, USHIO-FUKAI M: NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. (2000) 86(5):494–501.
   PubMed Web of Science ®Google Scholar
• SCHIFFRIN EL, PARK JB, INTENGAN HD, TOUYZ RM: of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation (2000) 101(14):1653–1659. 186. GHIODONI L, VIRDIS A, A et al: Effect of angiotensin II Type I receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension (2000) 35:501–506.
   Google Scholar
• VON ZUR MUHLEN B, KAHAN T, HAGG A, MILLGARD J, LIND L: Treatment with irbesartan or atenolol improves endothelial function in essential hypertension. J. Hypertens. (2001) 19(10):1813–1818.
   PubMed Web of Science ®Google Scholar
• PORTERI E, CIUCEIS C et al: Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus. Hypertension (2005) 45(4):659–665.
   PubMed Web of Science ®Google Scholar
• ELPU Q, PARK JB: Effect of amlodipine compared to atenolol on small arteries of previously untreated essential hypertensive patients.. J. Hypertens. (2002) 15(2 Part 1):105–110.
   Google Scholar
• VIRDIS A, GHIADONI L, ULERI S, MAGAGNA A, SALVETTI A: Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients. Hypertension (1997) 30(6):1606–1612.
   PubMed Web of Science ®Google Scholar
• SCHIFFRIN EL: Disparate effects of carvedilol versus metoprolol treatment of stroke-prone spontaneously hypertensive rats on endothelial function of resistance arteries.. Pharmacol (2000) 35(5):763–768.
   Google Scholar
• CHUNG NA, BEEVERS DG, LIP G: Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension. Blood Press. (2004) 13(3):183–189.
   PubMed Web of Science ®Google Scholar
• TZEMOS N, LIM PO, TM: Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation (2001) 104(5):511–514.
   PubMed Web of Science ®Google Scholar
• ABIOSE AK, MANSOOR GA, BARRY M, SOUCIER R, NAIR CK, HAGER D: of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy. Am. J. Cardiol (2004) 93(12):1564–1566.
   PubMed Web of Science ®Google Scholar
• MacDONALD JE, KENNEDY N, STRUTHERS AD: Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart (2004) 90(7):765–770.
   PubMed Web of Science ®Google Scholar
• GERHARD M, GANZ P: How do we explain the clinical benefits of estrogen? From bedside to bench. Circulation (1995) 92(1):5–8.
   PubMed Web of Science ®Google Scholar
• BUSH DE, JONES CE, BASS KM, WALTERS GK, BRUZA JM, OUYANG P: Estrogen replacement reverses endothelial dysfunction in postmenopausal women. Am. J. Med. (1998) 104:552–558.
   PubMed Web of Science ®Google Scholar
• McCROHON JA, WALTERS WA, ROBINSON JT et al: Arterial reactivity is enhanced in genetic males taking high dose estrogens. J. Am. Coll. Cardiol. (1997) 29:1432–1436.
   PubMed Web of Science ®Google Scholar
• McCROHON JA, ADAMS MR, McCREDIE RJ et al: Hormone replacement therapy is associated with improved arterial physiology in healthy postmenopausal women. Oxf (1996) 45:435–441.
   Google Scholar
• SORENSEN KE, DORUP I, HERMANN AP, MOSEKILDE L: Continued hormone replacement therapy does not protect women against the age-related decline in endothelial-dependent vasomotor function. Circulation (1998) 97:1234–1238.
   PubMed Web of Science ®Google Scholar
• KOTHNY W, ANGERER P, STORKS, VON SCHACKY C: Short term effects of omega-3 fatty acids on the radial artery of patients with coronary artery disease. Atherosclerosis (1998) 140(1):181–186.
   PubMed Web of Science ®Google Scholar
• VARIN R, MULDER P, RICHARD V et al.: Exercise improves flow-mediated vasodilatation of skeletal muscle arteries in rats with chronic heart failure. Role of nitric oxide, prostanoids, and oxidant stress. Circulation (1999) 99(22):2951–2957.
   Google Scholar
• HORNIG B, MAIER V, DREXLER H: Physical training improves endothelial function in patients with chronic heart failure. Circulation (1996) 93(2):210–214.
   PubMed Web of Science ®Google Scholar
• FUCHSJAGER-MAYRL G, PLEINER J, WIESINGER GF et al: Exercise training improves vascular endothelial function in 190. with Type 1 diabetes. Diabetes Care (2002) 25(10):1795–1801.
   Google Scholar
• HAMDY O, LEDBURY S, C et al.: Lifestyle improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care (2003) 26(7):2119–2125.
   PubMed Web of Science ®Google Scholar
• McLENACHAN JM, VITA J, FISH DR et al.: Early evidence of endothelial vasodilator dysfunction at coronary branch points. Circulation (1990) 82:1169–1173.
   PubMed Web of Science ®Google Scholar
• McLENACHAN JM, WILLIAMS JK, FISH RD, GANZ P, SELWYN AP: Loss of flow-mediated endothelium-dependent dilation occurs early in the development of atherosclerosis. Circulation (1991) 84:1273–1278.
   PubMed Web of Science ®Google Scholar
• PERTICONE F, CERAVOLO R, PURA A et al.: Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation (2001) 104(2):191–196.
   PubMed Web of Science ®Google Scholar
• HEITZERT, SCHLINZIG T, KROHN K, MEINERTZ T, MUNZEL T: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation (2001) 104:2673–2678.
   PubMed Web of Science ®Google Scholar
• PRASAD A, ZHU J, HALCOX JP, WACLAWIW MA, EPSTEIN SE, QUYYUMI AA: Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation (2002) 106(2):184–190.
   PubMed Web of Science ®Google Scholar
• HIGASHI Y, SASAKI S, NAKAGAWA K, MATSUURA H, CHAYAMA K, OSHIMA T: Effect of obesity on endothelium-dependent, nitric oxide-mediated vasodilation in normotensive individuals and patients with essential hypertension. Am. J. Hypertens. (2001) 14(10):1038–1045.
   PubMed Web of Science ®Google Scholar
• CHAMBERS JC, OBEID OA, JS: Physiological increments in plasma homocysteine induce vascular endothelial dysfunction in normal human subjects. Arterioscler. Thromb. Vasc. Biol. (1999) 19(12):2922–2927.
   PubMed Web of Science ®Google Scholar
• REIDY MA, SCHWARTZ SM: A technique to investigate surface morphology and endothelial cell erplication of small arteries; a study in acute angiotensin-induced hypertension. Micro vasc. Res. (1982) 24:158–167.
   PubMed Web of Science ®Google Scholar
• KUBO SH, RECTOR TS, BANK AJ, WILLIAMS RE, HEIFETZ SM: Endothelium-dependent vasodilation is in patients with heart failure. Circulation (1991) 84(01589–1589.
   PubMed Web of Science ®Google Scholar
• FILER AD, GARDNER-MEDWIN JM, THAMBYRAJAH J et al: Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa. Ann. Rheum. Dis. (2003) 62(2):162–167.
   PubMed Web of Science ®Google Scholar
• CLARKSON P, MONTGOMERY HE, MULLEN MJ et al: Exercise training enhances endothelial function in young men. jAm. Coll Cardiol (1999) 33(5):1379–1385.
   PubMed Web of Science ®Google Scholar
• MORENO H Jr, CHALON S, URAE A et al.: Endothelial dysfunction in human hand veins is rapidly reversible after smoking cessation. Am. J. Physiol (1998) 275(3 Part 2):H1040–H1045.
   Google Scholar
• LERMAN A, BURNETT JC Jr, HIGANO ST, McKINLEY LJ, DR Jr: Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation (1998) 97(21):2123–2128.
   PubMed Web of Science ®Google Scholar
• VERHAAR MC, HONING ML, VAN DAM T et al.: Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids. Cardiovasc. Res. (1999) 42(3):752–760.
   Google Scholar
• CELERMAJER DS, SORENSEN KE, GEORGAKOPOULOS D et al: Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation (1993) 88(5 Part 1):2149–2155.
   Google Scholar
• CELERMAJER DS, ADAMS MR, CLARKSON P et al: Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl.. (1996) 334(3):150–154.
   PubMed Web of Science ®Google Scholar
• COSENTINO F, HISHIKAWA K, KATUSIC ZS, LUSCHER TF: High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation (1997) 96:25–28.
   PubMed Web of Science ®Google Scholar
• DOSHI SN, McDOWELL IF, MOAT SJ et al.: Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation (2002) 105(1):22–26.
   PubMed Web of Science ®Google Scholar
• RAZA K, THAMBYRAJAH J, TOWNEND JN et al: Suppression of inflammation in primary systemic vasculitis vascular endothelial function: lessons for atherosclerotic disease? (2000) 102(13):1470–1472.
   Google Scholar
• WENNMALM A, BENTHIN G, EDLUND A et al.: Metabolism and excretion of nitric oxide in humans. An experimental and clinical study. Circ. Res. (1993) 73(6):1121–1127.
   Google Scholar
• ZEIHER AM, DREXLER H, WOLLSCHLAGER H, JUST H: Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation (1991) 84(5):1984–1992.
   PubMed Web of Science ®Google Scholar
• SAWYERR AM, SMITH MS, HALL A et al: Serum concentrations of von Willebrand factor and soluble thrombomodulin indicate alteration of endothelial function in inflammatory bowel diseases. Dig. Dis. Sci. (1995) 40(0793–799.
   PubMed Web of Science ®Google Scholar
• FARD A, TUCK CH, DONIS JA et al: Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with Type 2 diabetes.. Thromb. Vasc. Biol. (2000) 20(9):2039–2044.
   Google Scholar
• DONATELLI M, HOFFMANN E, COLLETTI I et al.: Circulating endothelin-1 levels in Type 2 diabetic patients with ischaemic heart disease. Acta Diabetol (1996) 33(3):246–248.
   PubMed Web of Science ®Google Scholar
• ELIASSON M, JANSSON JH, NILSSON P, ASPLUND K: Increased levels of tissue plasminogen activator antigen in essential hypertension. A population-based study in Sweden.. (1997) 15(4):349–356.
   Google Scholar
• BREVETTI G, MARTONE VD, DE CRISTOFARO T et al: High levels of adhesion molecules are associated with impaired endothelium-dependent vasodilation in patients with peripheral arterial disease. Thromb. Haemast. (2001) 85(1):63–66.
   PubMed Web of Science ®Google Scholar
• DAVI G, ROMANO M, MEZZETTI A et al: Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation (1998) 97(10):953–957.
   PubMed Web of Science ®Google Scholar
• MILLGARD J, HAGG A, SARABI M, LIND L: Captopril, but not nifedipine, improves endothelium-dependent vasodilation in hypertensive patients. J. Hum. Hypertens. (1998) 12(8):511–516.
   PubMed Web of Science ®Google Scholar
• TADDEI S, VIRDIS A, GHIADONI L et al.: Effect of calcium antagonist or 13 blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients.. (2001) 19(8):1379–1386.
   Google Scholar
• TADDEI S, VIRDIS A, GHIADONI L et al.: Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension (2001) 37(3):943–948.
   PubMed Web of Science ®Google Scholar
• ON YK, KIM CH, SOHN DW et al.: Improvement of endothelial function by amlodipine and vitamin C in essential hypertension. Korean I Intern. Med. (2002) 17(2):131–137.
   PubMedGoogle Scholar
• SCHIFFRIN EL, PARK JB, HD, TOUYZ RM: Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation (2000) 101(14):1653–1659.
   PubMed Web of Science ®Google Scholar
• ENCORE INVESTIGATORS: Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation (2003) 107(3):422–428.
   PubMed Web of Science ®Google Scholar
• GHIADONI L, MAGAGNA A, VERSARI D et al: Different effect of antihypertensive drugs on conduit artery function. Hypertension (2003) 41(6):1281–1286.
   PubMed Web of Science ®Google Scholar
• NIELSEN FS, ROSSING P, GALL MA et al: Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy. Scand. I Clin. Lab. Investig. (1997) 57(5):427–434.
   PubMed Web of Science ®Google Scholar
• BORCEA V, MORCOS M, B et al: Influence of ramipril on the course of plasma thrombomodulin in patients with diabetes mellitus. Vasa (1999) 28(3):172–180.
   PubMedGoogle Scholar
• TADDEI S, VIRDIS A, GHIADONI L, SUDANO I, SALVETTI A: Antihypertensive drugs and reversing of endothelial dysfunction in hypertension. Curt: Hypertens. Rep. (2000) 2(1):64–70.
   PubMedGoogle Scholar
• LI-SAW-HEE FL, BEEVERS DG, LIP GY: Effect of antihypertensive therapy using enalapril or losartan on haemostatic markers in essential hypertension: a pilot prospective randomised double-blind parallel group trial. Int. J. Cardiol (2001) 78(3):241–246.
   PubMed Web of Science ®Google Scholar
• SELJEFLOT I, ARNESEN H, P, ASPELIN T, KIERULF P: Effects of doxazosin and atenolol on circulating endothelin-1 and von Willebrand factor in hypertensive middle-aged men. ./. Cardiovasc. Phannacol (1999) 34(4):584–588.
   PubMed Web of Science ®Google Scholar
• MAKRIS TK, STAVROULAKIS GA, KRESPI PG et al: Fibrinolytic/hemostatic in arterial hypertension: response to treatment with irbesartan or atenolol. Hypertens. (2000) 13(7):783–778
   Web of Science ®Google Scholar
• TZEMOS N, LIM PO, TM: Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation (2001) 104(5):511–514.
   PubMed Web of Science ®Google Scholar
• MANCINI GB, HENRY GC, MACAYA C et al.: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation (1996) 94(3):258–265.
   PubMed Web of Science ®Google Scholar
• LEIGHTON F, CUEVAS A, GUASCH V et al: Plasma polyphenols and antioxidants, oxidative DNA damage and endothelial function in a diet and wine intervention study in humans. Drugs Exp. Chit. Res. (1999) 25(2-3):133–141.
   PubMedGoogle Scholar